RP1

The RP1 gene provides instructions for a photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) microtubule-associated protein — a scaffolding protein found inside the light-sensing cells of the retina. This protein helps stack the discs in the photoreceptor's outer segment correctly, which is essential for these cells to detect light. It works together with a related retinal protein called RP1L1 to support the shape and light sensitivity of rod photoreceptors, the cells responsible for night and side vision. The gene was first named ORP1 (oxygen-regulated protein-1) before it was linked to retinitis pigmentosa and renamed RP1. A notable feature of RP1 is that disease-causing changes can be inherited in either a dominant or a recessive way, which makes accurate genetic interpretation and counseling especially important.

When RP1 does not work correctly, photoreceptors gradually break down, which can lead to night blindness and a slow narrowing of the side (peripheral) field of vision — the classic pattern of retinitis pigmentosa. The effects of RP1 changes vary widely from person to person. In studies of people with two altered RP1 copies, the condition has been diagnosed as retinitis pigmentosa in most, but also as cone-rod dystrophy, macular dystrophy, Leber Congenital Amaurosis (LCA, or early-onset severe retinal dystrophy in others. Loss of the central retina (macular atrophy) was a common feature across that group. In a Japanese cohort, recessive RP1 disease tended to begin earlier and progress faster than the dominant form or than RP1-related cone/cone-rod dystrophy. One specific change near the end of the gene, c.5797C>T (p.Arg1933*), was linked to milder, mostly macular disease with better retinal function than other RP1 changes. RP1-related disease has also been associated with a longer eyeball and higher myopia (near-sightedness) in some patients.

RP1's link to retinitis pigmentosa is well established, and it appears repeatedly as a cause across many genetic studies of retinal disease. It is a relatively frequent cause of retinal degeneration in several populations, and how often it appears varies from one population to another. Researchers have documented that RP1 can act through both dominant and recessive inheritance, sometimes even within the same family. There is growing evidence that the type and location of a change within the gene influences the resulting diagnosis and how mild or severe it is.

Even among people with the same RP1 change, the age of onset, the diagnosis, and the speed of vision loss can differ, so an individual's course cannot be predicted from the gene result alone. It is not fully understood why some RP1 changes cause dominant disease while others cause recessive disease, which complicates genetic counseling. One early, not-yet-peer-reviewed report suggests that a change in a second gene (RIMS1) might worsen RP1-related disease in a single family, but this is a preliminary finding that needs confirmation.

As of this review, there is no approved treatment that targets the RP1 gene. In a mouse model of RP1-associated retinitis pigmentosa, a dual-AAV gene therapy (definition: A treatment that delivers a working copy of a gene into cells to take over for a copy that isn't functioning properly.) (delivering the gene in two viral halves that reassemble) preserved retinal structure and improved retinal function, which the researchers described as a promising early strategy. This is laboratory research in animals, not a therapy available to people. Separately, an antioxidant approach using N-acetylcysteine has been tested in people with retinitis pigmentosa broadly, based on the idea that reducing oxidative stress might help cone photoreceptors survive.

• Gene therapy tested in an RP1 mouse model

  Preclinical animal (mouse) research.

  What was found:

  The therapy restored RP1 protein, preserved photoreceptor structure, and improved retinal function and behavior at up to six months.

  Why it matters:

  It represents an early step toward a possible gene-based treatment for RP1 disease.

  Limitation: Results in mice do not establish safety or benefit in people; this is not an available treatment.

• The wide range of disease from recessive RP1 changes

  Observational human case series.

  What was found:

  Diagnoses ranged from retinitis pigmentosa to cone-rod dystrophy, macular dystrophy, Leber congenital amaurosis, and early-onset severe retinal dystrophy, with symptom onset between ages 4 and 30; certain missense changes in exon 2 were linked to later-onset retinitis pigmentosa.

  Why it matters:

  It shows that the same gene can produce very different diagnoses and ages of onset, and that the specific variant matters.

  Limitation: A small number of patients from selected clinics, so it cannot predict any individual's course.

• Variant type shapes the RP1 phenotype in a Japanese cohort

  Observational human cohort study.

  What was found:

  Recessive RP began earlier and progressed faster than the dominant form or cone/cone-rod dystrophy, and a particular insertion was the most common variant in this population.

  Why it matters:

  It supports a connection between the kind of RP1 change and the severity and pattern of disease.

  Limitation: Findings come from one population and may differ elsewhere.

• A specific RP1 change linked to milder disease

  Observational human study.

  What was found:

  Recessive patients carrying c.5797C>T mostly had macular dystrophy with better retinal function and later onset than patients without it, who mostly had severe retinitis pigmentosa.

  Why it matters:

  It suggests some RP1 variants may carry a milder outlook, which could help inform expectations.

  Limitation: Single-center, single-population data; associations do not guarantee an individual outcome.

• Dominant and recessive RP1 disease in one family

  Single-family human case report.

  What was found:

  The father, with one dominant change, had mild rod-cone dystrophy, while his daughter, who inherited two changes, had a more severe early-onset cone-rod dystrophy resembling recessive disease.

  Why it matters:

  It illustrates why dominant-versus-recessive interpretation of RP1 can be complex and why counseling assumptions need care.

  Limitation: One family only; broad conclusions cannot be drawn.

Because RP1 can be inherited in both a dominant and a recessive pattern, the implications for relatives depend on which pattern applies in your family, and this is worth clarifying with a genetics professional. Recessive RP1 disease can begin in childhood, so early eye assessment may be relevant for affected children in a family. Aside from these points, the general caregiver guidance shown on every gene page applies here.

• Is my RP1 change dominant or recessive, and what does that mean for my relatives?
• Which diagnosis best fits my clinical findings — retinitis pigmentosa, cone-rod dystrophy, or macular dystrophy?
• Does my specific RP1 variant have any known link to milder or more severe disease?
• How often should my vision and retina be monitored given my particular variant?
• Would I benefit from a low-vision or refractive assessment, since some RP1 cases involve higher myopia?
• Are there any registries or studies for RP1-related retinal disease that I could consider?

Confirming the exact RP1 change and whether it is dominant or recessive with a genetics professional can clarify what the result means for you and your relatives. You can explore whether any studies might be relevant using RP Hope's Clinical Trials Finder, which can screen with RP1 in mind, rather than judging eligibility from a gene page. RP Hope's guided pathway can help you find resources appropriate to your stage.